Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Multicenter study nets new lung tumor-suppressor gene

Multicenter study nets new lung tumor-suppressor gene

August 06, 2007

BOSTON--Collaborating scientists in Boston and North Carolina have found that a particular gene can block key steps of the lung cancer process in mice. The researchers report in the journal Nature that LKB1 is not only a "tumor-suppressor" gene for non-small cell lung cancer in mice, it also may be more powerful than other, better-known suppressors. The study will be published on the journal's Web site on Aug. 5 and later in a print version.

If further research shows LKB1 has a similar effect in human lung cells, it could influence the way non-small cell lung cancer is diagnosed and treated, says the study's senior author, Kwok-Kin Wong, MD, PhD, of Dana-Farber, one of three institutions, along with Massachusetts General Hospital and the University of North Carolina School of Medicine, leading the work. If tumors with LKB1 mutations are found to be especially fast-growing, for example, patients with such tumors might be candidates for more aggressive therapy.




People born with defective versions of LKB1 often develop Peutz-Jeghers syndrome, which is marked by intestinal growths and an increased risk for certain cancers. Non-inherited mutations of the gene have been found in some lung cancers. This suggested that LKB1 normally thwarts tumors from forming. Mutated versions may be unable to act as a brake on cancer.

To find out, the investigators ran a series of experiments in mice with a defective form of a gene called Kras, which drives the formation and growth of lung cancer. They tracked the development of lung cancer in animals with mutated LKB1 and compared it to the experience of animals with abnormalities in either of two well-known tumor-suppressor genes.

They found that while Kras "cooperated" with the mutated tumor-suppressor genes to produce lung cancer, it cooperated even more strongly with mutated LKB1. "The LKB1-deficient tumors grew more rapidly and spread more frequently than the others, and comprised all three types of non-small cell lung cancer -- squamous cell carcinoma, large-cell carcinoma, and adenocarcinoma -- rather than just one or two," Wong says. "This suggests that LKB1 plays a role at major stages of the tumors' development: initiation, differentiation of normal lung cells into cancer cells, and metastasis."

An examination of human non-small-cell lung tissue suggests LKB1 mutations play a role there as well. Of 144 samples analyzed, 34 percent of the lung adenocarcinomas and 19 percent of the squamous cell carcinomas contained abnormal versions of the gene, researchers report.

"We were surprised at how significant a role LKB1 mutations play in non-small cell lung cancer development in mice," say Wong, who is also an assistant professor of medicine at Harvard Medical School. "This suggests there may be additional lung tumor-suppressor genes yet to be discovered. We're currently examining whether these results apply to human lung cancers as well and, if so, how such information can improve treatment."

Dana-Farber Cancer Institute



Related Lung Cancer Current Events and Lung Cancer News Articles Lung Cancer Current Events and Lung Cancer News RSS Lung Cancer Current Events and Lung Cancer News RSS
MU study reveals effective anti-tobacco ads should either scare or disgust viewers
Now's the perfect time to increase anti-smoking campaigns - Nov. 20 is the American Cancer Society's Great American Smokeout.

Iressa proves just as effective as chemotherapy for lung cancer
Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.

Novel 4-drug combination proves safe for lung cancer treatment
The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.

The miseries of allergies just may help prevent some cancers, study finds
There may be a silver -- and healthy -- lining to the miserable cloud of allergy symptoms: Sneezing, coughing, tearing and itching just may help prevent cancer -- particularly colon, skin, bladder, mouth, throat, uterus and cervix, lung and gastrointestinal tract cancer, according to a new Cornell study.

Researchers aim to over-stress already taxed mantle cell lymphoma cells
Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them.

Researchers describe how chronic inflammation can lead to stomach cancer
A multi-center research team, led by Columbia University Medical Center, has uncovered a major contributor to the cause of stomach cancer - the second leading cause of cancer-related mortality in the world.

Media coverage of lung cancer is increasing, and increasingly negative, new report shows
CancerCare today announced that despite an overall increase in news reporting on lung cancer, the overall tone of lung cancer media coverage has become significantly more negative.

Major Source of Radon Exposure Overlooked at Former Ohio Uranium Processing Plant
University of Cincinnati (UC) scientists say that a recent scientific study of a now-closed uranium processing plant near Cincinnati has identified a second, potentially more significant source of radon exposure for former workers.

Study finds that practice makes perfect in lung cancer surgery
Patients operated on by surgeons who do not routinely remove cancer from the lungs may be at a higher risk for complications, according to a study conducted by researchers at Duke University Medical Center.

Red wine may lower lung cancer risk
Moderate consumption of red wine may decrease the risk of lung cancer in men, according to a report in the October issue of Cancer Epidemiology, Biomarkers & Prevention¸ a journal of the American Association for Cancer Research.
More Lung Cancer Current Events and Lung Cancer News Articles


How to Survive Lung Cancer - A Practical 12-Step Plan
by Michael Lloyd

Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer...



Lung Cancer: Myths, Facts, Choices--and Hope
by Claudia I. Henschke, Peggy McCarthy, Sarah Wernick

Lung cancer kills more women than breast cancer, more men than prostate cancer - because it's usually found too late. Claudia Henschke offers specific recommendations: who needs to be checked, where to be tested and what to expect. This book provides information on diagnosis, treatment and survival, accompanied by inspiring words from...



100 Questions & Answers About Lung Cancer (100 Questions & Answers about . . .)
by Karen Parles, Joan H. Schiller

This book deals with lung cancer from a doctor's perspective and a patient's...



Quick Facts on Lung Cancer (Quick Facts)
by American Cancer Society

Educate yourself about lung cancer What are your risk factors for lung cancer? Can you prevent it? How is lung cancer treated? What should you ask your doctor? QuickFACTS Lung Cancer is both a comprehensive and a quick read, with highlighted cover tabs for quick reference of specific topics. QuickFACTS Lung Cancer: Covers everything from risk factors to living well after cancer treatment ...



Lung Cancer: A Guide to Diagnosis and Treatment
by Walter Scott

Are You Receiving the Best Treatment for Lung Cancer? If you’ve been diagnosed with lung cancer, you’re probably frightened. And, you probably have many questions. You’re wondering about prognosis and treatment. What will the treatments be like? Will you have side effects? But…are you asking whether or not you’re receiving the best treatment possible? According to Walter Scott, M.D.,...



Lung Cancer: Making Sense of Diagnosis, Treatment, and Options
by Lorraine Johnston

Lung cancer is the number one cancer killer in the U.S., with over 170,000 new cases diagnosed each year. Despite this, it receives little attention from the media and little sympathy from the public. Those with lung cancer suffer more blame and stigma than other cancer patients, even though 50 percent of them are former smokers or have never smoked. Treatments for lung cancer can significantly...



Living with Lung Cancer: A Guide for Patients and Their Families
by Barbara G. Cox, David T. MD Carr, Eloise Harman, Robert E. Lee

Lung cancer is a scary disease, and the new patient is understandably confused and frightened. The future is uncertain, and it's filled with a dazzling array of unfamiliar medical and surgical terms and procedures. "Living With Lung Cancer" provides easy-to-understand information about diagnostic tests, treatments and their side effects, nutrition, the likely prognosis, even coping with emotions...



Voices of Lung Cancer: The Healing Companion: Stories for Courage, Comfort and Strength (Voices Of series)

Provided by the patients, their friends, families, and caregivers of those diagnaosed with lung cancer, these very personal stories offer inspired insight into the ways families and professionals care for both themselves and the patient, gain a deeper understanding of the relationships, and learn to come to terms with the end of life. Included are essays by medical experts about the science of...



Lung Cancer
by Jack A. Roth, James D. Cox, Waun Ki Hong

Lung cancer is a major cause of cancer-related deaths in men and women. However, since the first edition of Lung Cancer was published 14 years ago, rapid progress in the biology, prevention, diagnosis, and treatment of the disease has been...



Lung Cancer: Dana-Farber Cancer Institute Handbook (Dana-Farber Cancer Institute Handbooks)

Written by highly eminent authors, Lung Cancer - a handbook in the Dana-Farber Cancer Institute series - is produced in full color and is richly illustrated throughout, providing a review of each cancer including its incidence, epidemiology, etiology and histopathology, together with the clinical features. Diagnostic studies and current clinical and pathological staging are also given. Detailed...

© 2008 BrightSurf.com